Pierre Geborek
101 – 110 of 135
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2005
-
Mark
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
(
- Contribution to journal › Article
-
Mark
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
(
- Contribution to journal › Article
-
Mark
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
(
- Contribution to journal › Article
-
Mark
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
(
- Contribution to journal › Article
-
Mark
Response criteria for rheumatoid arthritis in clinical practice - how useful are they?
(
- Contribution to journal › Article
-
Mark
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
(
- Contribution to journal › Article
- 2004
-
Mark
Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al
(
- Contribution to journal › Letter
-
Mark
TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
(
- Contribution to journal › Scientific review
- 2003
-
Mark
Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept.
(
- Contribution to journal › Article
- 2002
-
Mark
Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
(
- Contribution to journal › Article